Literature DB >> 9474130

En bloc nephrectomy in patients undergoing post-chemotherapy retroperitoneal lymph node dissection for nonseminomatous testis cancer: indications, implications and outcomes.

P A Nash1, I Leibovitch, R S Foster, R Bihrle, R G Rowland, J P Donohue.   

Abstract

PURPOSE: We review the indications for nephrectomy at post-chemotherapy retroperitoneal lymph node dissection, identify patients at risk for nephrectomy and assess the impact of nephrectomy on outcome.
MATERIALS AND METHODS: Using a computerized data base and chart review we retrospectively reviewed the records of 848 patients who underwent retroperitoneal lymph node dissection after chemotherapy.
RESULTS: En bloc nephrectomy was performed at retroperitoneal lymph node dissection after chemotherapy in 162 of the 848 patients (19%). The indications for nephrectomy included contiguous involvement of perirenal structures in 73% of the cases, renal vein thrombosis in 6%, a poorly functioning or nonfunctioning renal unit in 5% and a combination of these conditions in 16%. Pathological studies of the hilum revealed cancer in 20% of the cases, teratoma in 49% and fibrosis in 31%. Patients requiring nephrectomy had significantly more advanced disease and larger disease volume at presentation and after chemotherapy. There were no significant differences in perioperative morbidity or mortality compared with patients who did not undergo nephrectomy. Only 3 patients required perioperative dialysis and none required long-term renal support.
CONCLUSIONS: These findings support en bloc nephrectomy at post-chemotherapy retroperitoneal lymph node dissection in select patients with large volume perihilar retroperitoneal disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9474130

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Surgical resection of urological tumor metastases following medical treatment.

Authors:  Axel Heidenreich; Stefan Wilop; Michael Pinkawa; Daniel Porres; David Pfister
Journal:  Dtsch Arztebl Int       Date:  2012-09-28       Impact factor: 5.594

Review 2.  [When is surgical resection of metastases in testicular germ cell tumors indicated and is there a scientific basis?]

Authors:  A Heidenreich; P Paffenholz; F Haidl; D Pfister
Journal:  Urologe A       Date:  2017-05       Impact factor: 0.639

3.  Surgery for retroperitoneal relapse in the setting of a prior retroperitoneal lymph node dissection for germ cell tumor.

Authors:  Geoffrey T Gotto; Brett S Carver; Pramod Sogani; Joel Sheinfeld
Journal:  Indian J Urol       Date:  2010 Jan-Mar

Review 4.  Complications of laparoscopic retroperitoneal lymph node dissection in testicular cancer.

Authors:  Patrick A Kenney; Ingolf A Tuerk
Journal:  World J Urol       Date:  2008-07-02       Impact factor: 4.226

5.  Outcomes following retroperitoneal lymph node dissection in postchemotherapy residual masses in advanced testicular germ cell tumors.

Authors:  Prabhjot Singh; Siddharth Yadav; Sanjay Mahapatra; Amlesh Seth
Journal:  Indian J Urol       Date:  2016 Jan-Mar

6.  Characterizing the Morbidity of Postchemotherapy Retroperitoneal Lymph Node Dissection for Testis Cancer in a National Cohort of Privately Insured Patients.

Authors:  Liam C Macleod; Saneal Rajanahally; Jasmir G Nayak; Brodie A Parent; Jorge D Ramos; George R Schade; Sarah K Holt; Atreya Dash; John L Gore; Daniel W Lin
Journal:  Urology       Date:  2016-01-21       Impact factor: 2.649

7.  Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.

Authors:  Axel Heidenreich; David Pfister
Journal:  Ther Adv Urol       Date:  2012-08

8.  [Postchemotherapy residual tumour resection in complex metastatic sites of advanced testicular germ cell tumours].

Authors:  P Paffenholz; D Pfister; A Heidenreich
Journal:  Urologe A       Date:  2016-05       Impact factor: 0.639

9.  Postchemotherapy Retroperitoneal Lymph Node Dissection in Patients With Nonseminomatous Testicular Cancer: A Single Center Experiences.

Authors:  Mohamadreza Nowroozi; Mohsen Ayati; Amir Arbab; Hassan Jamshidian; Hamidreza Ghorbani; Hassan Niroomand; Mohsen Taheri Mahmoodi; Erfan Amini; Sohrab Salehi; Hamid Hakima; Farid Fazeli; Saeid Haghdani; Alireza Ghadian
Journal:  Nephrourol Mon       Date:  2015-09-16
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.